Ruvalcaba-Limón Eva, de Jesús Garduño-Raya María, Bautista-Piña Verónica, Trejo-Martínez Claudia, Maffuz-Aziz Antonio, Rodríguez-Cuevas Sergio
Departamento de Oncología Mamaria Quirúrgica, Instituto de Enfermedades de la Mama (IEM) de la Fundación del Cáncer de Mama, A. C. (FUCAM), México DF, Mexico.
Departamento de Patología, Instituto de Enfermedades de la Mama (IEM) de la Fundación del Cáncer de Mama, A. C. (FUCAM), México DF, Mexico.
Cir Cir. 2014 Mar-Apr;82(2):129-41.
Sentinel lymph node biopsy in patients with ductal carcinoma in situ still controversial, with positive lymph node in range of 1.4-12.5% due occult invasive breast carcinoma in surgical specimen.
To know the frequency of sentimel node metastases in patients with ductal carcinoma in situ, identify differences between positive and negative cases.
Retrospective study of patients with ductal carcinoma in situ treated with sentinel lymph node biopsy because mastectomy indication, palpable tumor, radiological lesion = 5 cm, non-favorable breast-tumor relation and/or patients whom surgery could affect lymphatic flow drainage.
Of 168 in situ carcinomas, 50 cases with ductal carcinoma in situ and sentinel lymph node biopsy were included, with a mean age of 51.6 years, 30 (60%) asymptomatic. The most common symptoms were palpable nodule (18%), nipple discharge (12%), or both (8%). Microcalcifications were common (72%), comedonecrosis pattern (62%), grade-2 histology (44%), and 28% negative hormonal receptors. Four (8%) cases had intra-operatory positive sentinel lymph node and one patient at final histo-pathological study (60% micrometastases, 40% macrometastases), all with invasive carcinoma in surgical specimen. Patients with intra-operatory positive sentinel lymph node where younger (44.5 vs 51 years), with more palpable tumors (50% vs 23.1%), and bigger (3.5 vs 2 cm), more comedonecrosis pattern (75% vs 60.8%), more indifferent tumors (75% vs 39.1%), and less cases with hormonal receptors (50% vs 73.9%), compared with negative sentinel lymph node cases, all these differences without statistic significance.
One of each 12 patients with ductal carcinoma in situ had affection in sentinel lymph node, so we recommend continue doing this procedure to avoid second surgeries due the presence of occult invasive carcinoma.
导管原位癌患者前哨淋巴结活检仍存在争议,由于手术标本中存在隐匿性浸润性乳腺癌,前哨淋巴结阳性率在1.4%至12.5%之间。
了解导管原位癌患者前哨淋巴结转移的频率,确定阳性和阴性病例之间的差异。
对因乳房切除术指征、可触及肿瘤、放射学病变≥5cm、乳房-肿瘤关系不佳和/或手术可能影响淋巴引流的患者进行前哨淋巴结活检治疗的导管原位癌患者进行回顾性研究。
在168例原位癌中,纳入了50例导管原位癌并进行前哨淋巴结活检的病例,平均年龄51.6岁,30例(60%)无症状。最常见的症状是可触及结节(18%)、乳头溢液(12%)或两者皆有(8%)。微钙化常见(72%),粉刺坏死模式(62%),组织学2级(44%),28%激素受体阴性。4例(8%)病例术中前哨淋巴结阳性,1例患者最终组织病理学研究显示(60%微转移,40%宏转移),所有手术标本均有浸润性癌。与前哨淋巴结阴性病例相比,术中前哨淋巴结阳性的患者更年轻(44.5岁对51岁),可触及肿瘤更多(50%对23.1%),肿瘤更大(3.5cm对2cm),粉刺坏死模式更多(75%对60.8%),非特殊型肿瘤更多(75%对39.1%),激素受体阳性病例更少(50%对73.9%),所有这些差异均无统计学意义。
每12例导管原位癌患者中有1例前哨淋巴结受累,因此我们建议继续进行该操作,以避免因隐匿性浸润性癌的存在而进行二次手术。